CD44 and neoplasm: In view of PKMYT1AR function in NSCLC, the authors also targeted it in vitro and in tumor xenografts, showing that its inhibition through ASOs can efficiently impair tumor stem features, as self-renewal, and the expression of stem cell markers, as CD44 and SOX2.